|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 13, Issue 8, 2639-2650, August 2002

and
*Departments of Pathology, and Molecular and Cellular Biology,
Baylor College of Medicine, Houston, Texas 77030-3498; and
Department of Biochemistry and Molecular Biology and
Complex Carbohydrate Research Center, University of
Georgia, Athens, Georgia 30602-7229
| |
ABSTRACT |
|---|
|
|
|---|
Protein folding and quality control in the early secretory pathway
function as posttranslational checkpoints in eukaryote gene expression.
Herein, an aberrant form of the hepatic secretory protein
1-antitrypsin was stably expressed in a human embryonic kidney cell line to elucidate the mechanisms by which glycoprotein endoplasmic reticulum-associated degradation (GERAD) is administered in
cells from higher eukaryotes. After biosynthesis, genetic variant PI Z
underwent alternative phases of secretion and degradation, the latter
of which was mediated by the proteasome. Degradation required release
from calnexin- and asparagine-linked oligosaccharide modification by
endoplasmic reticulum mannosidase I, the latter of which occurred as PI
Z was bound to the molecular chaperone grp78/BiP. That a distinct GERAD
program operates in human embryonic kidney cells was supported by the
extent of PI Z secretion, apparent lack of polymerization, inability of
calnexin to participate in the degradation process, and sequestration
of the glycoprotein folding sensor UDP-glucose:glycoprotein
glucosyltransferase in the Golgi complex. Because
UDP-glucose:glycoprotein glucosyltransferase sustains calnexin binding,
its altered distribution is consistent with a GERAD program that
hinders the reentry of substrates into the calnexin cycle, allowing
grp78/BiP to partner with a lectin, other than calnexin, in the
recognition of a two-component GERAD signal to facilitate substrate
recruitment. How the processing of a mutant protein, rather than the
mutation itself, can contribute to disease pathogenesis, is discussed.
| |
INTRODUCTION |
|---|
|
|
|---|
Numerous checkpoints exist in the eukaryote to maintain the
integrity of genomic information (reviewed by Hartwell and Weinert, 1989
; Zhou and Elledge, 2000
). Importantly, these are not limited to
the nucleus or restricted to the surveillance of DNA. Rather, these
systems extend to compartments of the cell in which the conformational
maturation of expressed gene products is facilitated to ensure the
structural fidelity of the proteome (Pandey and Mann, 2000
), which is,
by definition, the expressed cellular genome.
In the eukaryote, secretory and cell surface proteins are transported
through a series of membranous organelles before their final deployment
(reviewed by Ellgaard and Helenius, 2001
). The first of these
compartments is the endoplasmic reticulum (ER) where nascent
polypeptides rely on molecular chaperones to facilitate conformational
maturation (reviewed by Gething and Sambrook, 1992
), the latter of
which is essential for biological activity. As a rule, protein delivery
to the Golgi is tightly coupled to the acquisition of native protein
structure (reviewed by Rothman, 1987
; Klausner and Sitia, 1990
).
Misfolded polypeptides and unassembled protein subunits are usually
subjected to ER-associated degradation (ERAD) (McCracken and Brodsky,
1996
; Sommer and Wolf, 1997
; Fewell et al., 2001
), which
concludes with the retro-translocation of substrates into the cytoplasm
before elimination by the multicatalytic proteasome (reviewed by
Bonifacino and Weissman, 1998
). Although ERAD likely contributes to the
molecular pathogenesis and phenotypic variation associated with many
loss- and gain-of-toxic function disorders (reviewed by Thomas et
al., 1995
; Choudhury et al., 1997
; Cabral et
al., 2001
), the exact mechanisms by which the entire process is
orchestrated, especially at the earliest steps, is only now becoming
clear (Ellgaard et al., 1999
).
Protein folding and quality control is best understood for those
molecules to which
Glc3Man9GlcNAc2
is covalently attached (reviewed by Helenius, 1994
) during
translocation into the ER (reviewed by Kornfeld and Kornfeld, 1985
).
The hydrolysis of two terminal glucose units by glucosidase I and
glucosidase II (Hammond et al., 1994
) promotes
cotranslational association with the ER lectins calnexin and
calreticulin (Hammond and Helenius, 1995
), both of which bind
high-mannose monoglucosylated oligosaccharides (reviewed by Ellgard
et al., 1999
; Parodi, 2000
). The eventual removal of
the remaining glucose by glucosidase II dissociates the
glycoprotein-lectin complexes (Hebert et al., 1995
;
VanLeeuwen and Kearse, 1996
). Reentry into the calnexin cycle, which
can facilitate additional folding (Hammond et al., 1994
),
requires oligosaccharide reglucosylation by the glycoprotein folding
sensor UDP-glucose:glycoprotein glucosyltransferase (UGT) (Zapun
et al., 1997
), an ER resident protein in rat liver
hepatocytes (Trombetta et al., 1991
). Conformational
maturation abolishes recognition by UGT (Sousa et al.,
1992
), ensuring that native glycoproteins are released from the
calnexin cycle and transported to the Golgi complex (Hammond et
al., 1994
).
A picture recently emerged in which the modification of
asparagine-linked
Man9GlcNAc2 by an
ER-situated
-1,2 mannosidase (i.e., ER mannosidase I) (Gonzalez
et al., 1999
; Tremblay and Herscovics, 1999
) plays a central
role in generating a common signal that targets a diverse set of
aberrant and unassembled glycoproteins for clearance from the ER
(reviewed by Frigerio and Lord, 2000
), by a process recently coined
glycoprotein ERAD (GERAD) (reviewed by Cabral et al.,2001
).
Because the glycan modification does not target correctly folded
glycoproteins for degradation, nonnative protein structure likely
functions as an inherent aglycone (i.e., noncarbohydrate) GERAD signal
component (Cabral et al., 2001
). Although asparagine-linked
glycosylation and the earliest asparagine-linked glycan-processing
events are conserved from yeast to mammals (Gonzalez and Jordan, 2000
;
Parodi, 2000
; Herscovics, 2001
), examples exist in which a given
glycoprotein substrate is handled differently in distinct animal cell
lines (Sitia et al., 1990
; Qu et al., 1996
;
Novoradovskaya et al., 1998
; Cabral et al.,
2000
). These observations, plus the apparent discrepancy as to whether
calnexin promotes, or prevents, the degradation of bound glycoprotein
substrates (Ayalon-Soffer et al., 1999
), suggests that
different strategies might orchestrate GERAD in distinct animal cells
(reviewed by Cabral et al., 2001
).
Serum
1-antitrypsin (AAT) deficiency has provided a medically
relevant paradigm to investigate ER quality control as a
posttranslational checkpoint in eukaryote genome expression (reviewed
by Sifers et al., 1992
). The spontaneous loop-sheet
polymerization (Lomas et al., 1992
) of a late folding
intermediate (Yu et al., 1995
) is responsible for hindering
the secretion of genetic variant PI Z from liver hepatocytes (Sifers
et al., 1992
). Chronic obstructive pulmonary disease and
liver cirrhosis are the associated loss- and gain-of-toxic function
disorders, respectively (reviewed by Perlmutter and Pierce, 1989
;
Kopito and Ron, 2000
; Carrell and Lomas, 2002
), and the latter has been
linked to a hindered rate of PI Z polymer degradation (Wu et
al., 1994
), possibly augmenting the accumulation of insoluble
polymers in the hepatocyte ER (Carlson et al., 1988
; Graham
et al., 1990
; Volpert et al., 2000
). In the murine hepatoma cell line Hepa1a, modification by ER mannosidase I
leads to the proteasomal degradation of terminally misfolded AAT by
abrogating its dissociation from calnexin (Liu et al., 1999
), resulting from the attenuated rate in which glucose is removed
by glucosidase II in the absence of the full compliment of mannose
units (Grinna and Robbins, 1980
). That calnexin can function as a bona
fide participant in GERAD, at least in Hepa1a, was established by
several additional lines of evidence (Liu et al., 1999
),
including degradation by a coexisting nonproteasomal pathway in
response to the spontaneous formation of variant PI Z loop-sheet
polymers, which prevents posttranslational physical engagement with the
ER lectin (Cabral et al., 2000
). In the present study,
variant PI Z was used as a reporter protein to characterize the
administration of GERAD in the human embryonic kidney (HEK) 293 cell
line as a first step toward elucidating the specific organizational
differences in quality control systems among cells in higher
eukaryotes. Alternative phases of secretion and degradation were
detected after biosynthesis. Degradation was mediated by the
ubiquitin-proteasome system, and required the modification of
asparagine-linked glycans by ER mannosidase I, but only after release
from calnexin and assembly with grp78/BiP. Unlike its reticular
distribution in Hepa1a, the bulk of UGT is sequestered downstream of
the ER in HEK293, providing a mechanism by which the reentry of PI Z
into the calnexin cycle is eventually blocked, and leads to physical
interaction with grp78/BiP. Taken together, the data uncover a
posttranslational mechanism that mediates the transfer of an aberrant
glycoprotein into an alternate folding system before degradation, and
identify the existence of distinct GERAD programs that diverge in the
manner by which a two-component GERAD signal is recognized.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Stable Cell Transfection, Selection, and Expansion
The recombinant human
1-antitrypsin PI Z variant cDNA (Le
et al., 1990
) was subcloned into the unique EcoRI
site of pCDNA3.1/Zeo(+) (Invitrogen, Carlsbad, CA) to generate an
appropriate mammalian expression vector. The LipofectAMINE-mediated
transfection (Invitrogen) of the cell line HEK293 (peak; Edge
Biosystems, Gaithersburg, MD) led to the isolation and expansion
of the representative stable cell line HEK/Z-1 after zeocin
(Invitrogen) selection.
Metabolic Radiolabeling
Semiconfluent monolayers of HEK/Z-1 were grown at 37°C in a
humidified CO2 atmosphere to equal cell density
in 100-mm dishes precoated at room temperature with
poly-D-lysine (0.025 mg/ml). Metabolic radiolabeling was
preceded by a 30-min methionine starvation at 37°C in methionine-free
DMEM (ICN Biomedical, Inc., Aurora, OH) containing 10% fetal
calf serum before a 15-min pulse with [35S]methionine (Easy Tag Express Mix;
PerkinElmer Life Sciences, Boston, MA) as described previously (Liu
et al., 1997
). Monolayers were washed with Dulbecco's
phosphate-buffered saline (Invitrogen) to remove unincorporated
radiolabel and then chased for the desired period at 37°C with
methionine starvation medium supplemented with a 10-fold excess of
unlabeled methionine. Unless otherwise stated, the inhibition of
specific glycosidase activities was accomplished by a 60-min incubation
of cells at 37°C in normal growth medium containing the desired
compound before methionine starvation. The specified compound was also
included in the media used for methionine starvation, pulse
radiolabeling, and the chase. Proteasomal activity was inhibited with
0.25 mM lactacystin (E.J. Corey Laboratories, Harvard Medical School,
Cambridge, MA). ER mannosidase I was inhibited with 0.1 mM kifunensine
(Toronto Research Chemicals) or 1 mM 1-deoxymannojirimycin
(Roche Applied Science, Indianapolis, IN). ER mannosidase II was
inhibited with 0.1 mM swainsonine (Sigma-Aldrich, St. Louis, MO).
Glucosidases I and II were inhibited with 0.2 mg/ml castanospermine
(Roche Applied Science). Routine buffers and salts were procured from
Sigma-Aldrich.
Cell Lysis and Immunoabsorption
Equal cell monolayers grown to semiconfluence in 100-mm dishes
were lysed by scraping in buffered NP-40 detergent (Calbiochem, San
Diego, CA) at 4°C (Liu et al., 1997
) either immediately
after the pulse or after the chase as described previously (Le et
al., 1990
). Cell media were collected at each time point and
adjusted to 0.5% NP-50. Centrifugation of all samples (3000 × g, 5 min, 4°C) was used for the removal of NP-40 insoluble
material before the addition of an IgG fraction of goat anti-human
1-antitrypsin (ICN Biomedical Research Products), which was
preimmobilized to protein G-agarose (Calbiochem, Toronto, ON) as
described previously (Le et al., 1994
). The immunoabsorption
of variant PI Z was accomplished during a 2-h incubation, with constant
rotation, at 4°C, and then washed as described previously (Liu
et al., 1999
). For the detection of radiolabeled PI Z bound
to either calnexin or grp78/BiP, cell lysates were incubated with a
rabbit polyclonal rabbit antibody raised against the cytoplasmic tail
of canine calnexin (StressGen, Victoria, British Columbia, Canada) or
the KDEL retrieval motif (StressGen), respectively. In all procedures,
equal aliquots of radiolabeled PI Z immunoprecipitated from the cell
lysate and medium were resolved by SDS-PAGE and then detected by
fluorographic enhancement of the vacuum-dried gels before quantitation
by liquid scintillation counting of excised gel pieces (Le et
al., 1994
). The percentage of pulse-radiolabeled PI Z subjected to
degradation was determined as that amount lost from the initial pulse
and not recovered in either the cell lysate or medium. Lithium dodecyl sulfate extraction of the insoluble NP-40 cell lysate pellet from each
time point, in combination with immunoprecipitation with
1-antitrypsin antiserum as described previously (Graham et
al., 1990
), was used to detect insoluble PI Z polymers.
Enhanced Chemiluminescence (ECL) Western Blotting
After resolution by SDS-PAGE, immunoprecipitated proteins were
electrophoretically transferred onto Hybond ECL nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ) and blotted as described previously (Choudhury et al., 1997
).
Ubiquitin-conjugated PI Z was detected with a 1:500 dilution of a
polyclonal rabbit antiserum against bovine ubiquitin (Calbiochem). The
detection of calnexin was accomplished with a 1:1000 dilution of a
polyclonal rabbit antiserum against a synthetic peptide homologous to
the cytoplasmic tail of the canine homolog (StressGen). Grp78/BiP was
detected with a 1:400 dilution of a purified monoclonal antibody against a synthetic peptide homologous to the six carboxyl-terminal residues of the rat homolog (KDEL retrieval motif) (StressGen). Incubation with conjugated secondary antibodies, subsequent washings, and the use of detection reagents was performed in a manner identical to that reported previously (Choudhury et al., 1997
).
Indirect Immunofluorescence Microscopy
HEK293 and Hepa1a cells were grown on glass coverslips to
~70% confluence, rinsed with phosphate-buffered saline (PBS), and fixed for at least 10 min in methanol at
20°C. The cells were then
rehydrated in PBS and incubated separately with the following antibodies: rabbit polyclonal antiserum against rat
UDP-glucose:glycoprotein glucosyltransferase (a generous gift from Dr.
Armando Parodi, Instituto de Investigaciones Bioquimicas, Buenos Aires,
Argentina), rabbit polyclonal antiserum against the catalytic domain of
-mannosidase II (Moremen et al., 1991
), a polyclonal
rabbit antiserum against a synthetic peptide homologous to the
cytoplasmic tail of canine calnexin (StressGen), a rabbit polyclonal
antiserum against recombinant human calreticulin (Affinity Bioreagents,
Golden, CO), and polyclonal rabbit antiserum against the KDEL retrieval
motif (StressGen). All primary antisera recognized the appropriate
band(s) in ECL Western blotting of soluble NP-40 cell lysates and were
incubated with cells for 1 h at 37°C in a humid chamber. After
several washes in PBS, the cells were incubated with species-specific
fluorescein isothiocyanate-conjugated donkey anti-rabbit IgG (Santa
Cruz Biotechnology, Santa Cruz, CA). In all cases, antibody specificity
was again tested by incubating coverslips with each primary antibody
and the cross-species secondary antibody to ensure the absence of immunofluorescence. Brefeldin A (Epicenter Technologies, Madison, WI)
was added to cells 1.5 h before methanol fixation at a final concentration of 2 µg/ml where indicated to redistribute Golgi proteins into the ER (Lippincott-Schwartz et al., 1989
).
Samples were viewed by epifluorescence by using an Optiphot microscope equipped with a 40× fluor objective (Nikon, Melville, NY). Images were
acquired using a DMX-1200 digital camera (Nikon).
| |
RESULTS |
|---|
|
|
|---|
Alternative Phases of Secretion and Disposal
The fate of variant PI Z after stable transfection of HEK293 cells
(cell line HEK/Z1) was monitored by pulse-chase radiolabeling and
immunoprecipitation (see MATERIALS AND METHODS). The secretion of
radiolabeled PI Z was not initiated until after the first 60 min of
chase (Figure 1A) and was essentially
complete by 3 h (Figure 1B) at which time 40% of the
pulse-radiolabeled molecules were detected in the medium (Figure 1A).
The slower migration in SDS-PAGE, relative to the intracellular
species, reflects the covalent addition of sialic acid to
asparagine-linked oligosaccharides during transport although the
trans-Golgi network (Le et al., 1990
). Only 10%
of the radiolabeled molecules remained in the cell lysate at 7 h of chase (Figure 1B), and none were detected in the insoluble NP-40
cell lysate at any time point (Figure 1A), indicating that 50% had
been degraded. Because degradation had not yet been initiated at 3 h of chase (Figure 1B), the fate of pulse-radiolabeled PI Z could be
separated into distinct, and sequential, phases of secretion and
disposal. Importantly, neither the extent of PI Z secretion nor the
rate of its degradation deviated by >20% when analyzed in three
additional stable transfectants (our unpublished data).
|
Degradation by Proteasome
The proteasome has been implicated in mediating the degradation of
numerous aberrant proteins from the ER (reviewed by Bonifacino and
Weissman, 1998
). To determine whether the multicatalytic system contributes to the turnover of PI Z in HEK/Z1, the pulse-radiolabeled molecules were subjected to a 5-h chase in medium containing 0.025 mM
lactacystin, an irreversible covalent inhibitor of the proteasome (Fenteany et al., 1995
). PI Z turnover was completely
arrested under these conditions (Figure
2A, compare lanes 2 and 3), and quantitative analysis of the immunoprecipitated material revealed that
the percentage of radiolabeled molecules secreted into the medium was
enhanced ~50% (Figure 2, compare lanes 4 and 5). The latter
observation did not result from the saturation of ER retention machinery, because none of the secretion-incompetent AAT variant null(Hong Kong) (Sifers et al., 1989
; Le et al.,
1990
) was secreted under an identical set of conditions (our
unpublished data). The data indicate that the elimination of
secretion-impaired PI Z is mediated by the proteasome in HEK293.
|
Sequential Interaction with Molecular Chaperones Calnexin and grp78/BiP
A transient interaction with calnexin, resulting from loop-sheet
polymerization, ablates the secretion of all but ~10-15% of
pulse-radiolabeled PI Z from the hepatoma cell line Hepa1a (Le et
al., 1992
; Cabral et al., 2000
). Considering the extent of PI Z secretion from HEK/Z-1, coimmunoprecipitation in combination with ECL Western blotting was a means to detect and identify any molecular chaperones that might bind to variant PI Z as an alternate ER
retention mechanism, because these interactions are often responsible for both facilitating protein folding and retaining misfolded proteins
in the early secretory pathway (reviewed by Gething and Sambrook,
1992
). First, we asked whether a physical association with calnexin,
which facilitates the folding of numerous glycoproteins, including AAT
in hepatoma cells (Ou et al., 1993
), was detectable. Consistent with this prediction, immunoreactive calnexin was detected in PI Z immunoprecipitates generated from HEK/Z-1 cells under steady-state conditions (Figure 3A, lane
2). Importantly, no signal was detected when the samples were incubated
with protein G-agarose alone (our unpublished data). Blotting with the
anti-KDEL antiserum, which recognizes a common epitope for ER retention
(Vaux et al., 1990
), resulted in the detection of
coimmunoprecipitated grp78/BiP (Figure 3A, lane 2). The specificity of
the interaction was established by the absence of coimmunoprecipitating
grp94, which is one of the two most abundant KDEL-bearing proteins
(Koch et al., 1986
), as confirmed by our analysis of an
NP-40 HEK/Z1 cell extract (Figure 3A, lane 1). Importantly, no
interaction with calreticulin, a soluble homolog of calnexin (Danilczyk
et al., 2000
), or additional ER chaperones, was detected
under numerous conditions (our unpublished data).
|
Coimmunoprecipitation with the chaperone antisera, in combination with pulse-chase radiolabeling allowed us to elucidate the time course in which PI Z bound calnexin and grp78/BiP after a 15-min pulse with [35S]methionine. Radiolabeled PI Z was maximally bound to calnexin immediately after biosynthesis, with little, or no, physical interaction with grp78/BiP (Figure 3B, lane 1). Physical interaction with the ER lectin gradually diminished until it was almost absent at 3 h of chase (Figure 3B, lane 4). Conversely, physical interaction with grp78/BiP increased until maximal binding was detected at 3 h (Figure 3B, lane 4) and diminished thereafter (Figure 3B, lanes 4-6).
Because the initiation of degradation did not occur until after 3 h of chase (Figure 1B), a time point in which the intracellular fraction of PI Z was no longer bound to calnexin (Figure 3B, lane 4),
we asked whether physical interaction with the ER lectin was even
necessary for intracellular turnover. HEK/Z1 cells were incubated with
castanospermine, an inhibitor of ER glucosidases (Elbein, 1991
), before
the 15-min pulse with [35S]methionine to arrest
the removal of all three terminal glucose units from the
asparagine-linked
Glc3Man9GlcNAc2
precursor (Kornfeld and Kornfeld, 1985
), and block cotranslational
assembly between newly synthesized PI Z and calnexin. Under these
conditions physical interaction with calnexin was prevented, but
interaction with grp78/BiP was observed (our unpublished data).
Importantly, PI Z turnover did not deviate by >16% during a 5-h chase
compared with control (Table 1).
Furthermore, degradation was almost completely arrested under these
conditions when cells were coincubated with lactacystin (Table 1) and
ruled out the possibility that intracellular clearance had been
accomplished by an alternate nonproteasomal disposal pathway, as occurs
in Hepa1a where coexisting proteolytic systems operate (Cabral et
al., 2000
).
|
Next, the fate of pulse-radiolabeled PI Z was examined in cells in
which castanospermine was added immediately after pulse radiolabeling
(Figure 4, step 2) to prevent the
posttranslational removal of glucose by ER glucosidase I, which
dissociates glycoprotein-calnexin complexes (Hebert et al.,
1995
). Under these conditions, physical interaction with grp78/BiP was
entirely blocked (our unpublished data), and variant PI Z
degradation was arrested (Table 1). These results indicated that the
molecules of PI Z eventually bound to grp78/BiP were first engaged with
calnexin, and confirms that release from the ER lectin is necessary for
degradation. Taken together, these findings indicate that PI Z
secretion coincides with a period in which all the newly synthesized
molecules are undergoing physical interaction with calnexin, and that
degradation by the proteasome is preceded by physical engagement with
grp78/BiP, and requires release from the ER lectin (Figure 4).
|
Requirement for Modification by ER Mannosidase I
Next, we asked whether the modification of asparagine-linked
oligosaccharides by ER mannosidase I (Figure
5A) generates a signal that mediates the
recognition of secretion-impaired variant PI Z by GERAD machinery for
degradation by the proteasome. Because
1-antitrypsin contains three
asparagine-linked oligosaccharides (Long et al., 1984
), the
glycan modification is indirectly detected by the accelerated mobility
of the ER-retained radiolabeled molecules in SDS-PAGE (Le et
al., 1992
; Liu et al., 1997
). The aberrant mobility was
maximally detected at 3 h of chase (Figure 1A), at which time the
secretion-impaired fraction had been released from calnexin and was
bound to grp78/BiP (Figure 3B), before the onset of intracellular
degradation (Figure 1B). To determine whether modification by ER
mannosidase I was responsible for the electrophoretic anomaly, and was
required for proteasomal degradation in HEK293, we examined the effect
of kifunensine, an inhibitor of the processing enzyme (Weng and Spiro,
1993
). During a 5-h chase, PI Z degradation was completely arrested
(Table 1), as was the altered electrophoretic mobility in SDS-PAGE
(Figure 5B, compare lanes 2 and 3). In contrast, incubation with
swainsonine (Weng and Spiro, 1996
), an inhibitor of ER mannosidase II
(Figure 5A), had no detectable effect (Table 1).
|
In cells treated with kifunensine, the percentage of radiolabeled
molecules secreted into the medium increased almost 50% (Figure 5B,
compare lanes 4 and 5), similar to that observed when degradation was
arrested with lactacystin (Figure 2A). As before, the altered
electrophoretic mobility of the secreted fraction (Figure 5B, lane 5)
reflects the absence of sialic acid addition to asparagine-linked
oligosaccharides in the late Golgi complex, which occurs in response to
the arrested removal of mannose (Sifers et al., 1989
). That
enhanced secretion of PI Z did not result from the saturation of the
general ER retention machinery was confirmed by the absence of
terminally misfolded
1-antitrypsin variant null(Hong Kong) secretion
(Le et al., 1990
) under an identical set of conditions (our
unpublished data). Furthermore, treatment with kifunensine
arrested the proteasome-mediated degradation of PI Z in HEK/Z-1
preincubated with castanospermine (Table 1), which prevented physical
assembly with calnexin (Figure 4, step 1). Taken together, these data
indicate that glycan modification by ER mannosidase I plays a central
role in tagging variant PI Z for elimination by the proteasome in
HEK293, after release from calnexin and engagement with grp78/BiP.
Differential Distribution of UGT in Secretory Pathway
The differential ability of calnexin to actively participate in
proteasomal degradation was a definite clue that a distinct GERAD
program, and not merely overlapping pathways, might operate in HEK293
and Hepa1a. Considering the duration in which PI Z binds calnexin, we
concluded that multiple rounds of binding to the ER lectin likely
occur. For this reason, we asked whether a distinct mechanism is
responsible for eventually inhibiting the reentry of PI Z into the
calnexin cycle (Figure 4, step 2), favoring engagement with grp78/BiP
(Figure 4, step 4). Otherwise, modification by ER mannosidase I would
be counterproductive and block PI Z turnover in response to its
abrogated dissociation from a population of calnexin unable to
participate in GERAD. Because
Man7GlcNAc2 is a very poor
substrate for UGT (Parodi et al., 1983
), we asked whether
processing by ER mannosidase II, in addition to ER mannosidase I
(Figure 5A), might be responsible for eventually blocking the interaction with calnexin. To address this possibility, cells were
treated under steady-state conditions with 1-deoxymannojirimycin, an
inhibitor of
1,2-mannosidases I and II (Elbein, 1991
) to prevent formation of the asparagine-linked
Man7GlcNAc2 structure
(Figure 5A). Although PI Z degradation was completely arrested (Table 1), likely owing to the inhibition of ER mannosidase I, grp78/BiP-bound PI Z increased threefold (Figure 5C, compare lanes 2 and 3), whereas the number of molecules bound to calnexin was similar to that of
control (Figure 5C, compare lanes 2 and 3). Although the hypothesis was
negated, the data are consistent with the notion that formation of the
GERAD signal requires modification by ER mannosidase I when PI Z is
bound to grp78/BiP (Figure 4, step 5).
Because asparagine-linked oligosaccharide reglucosylation induces
glycoprotein assembly with calnexin (Zapun et al., 1977
), in
the next set of experiments we asked whether an elevated concentration of grp78/BiP might provide a subtle competitive advantage that eventually blocks recognition by UGT, thereby hindering the reentry of
PI Z into the calnexin cycle. However, no significant difference in the
total intracellular concentrations of the two proteins was detected by
ECL Western blotting of soluble NP-40 cell extracts generated from
HEK/Z-1, the untransfected HEK293 cell host, or Hepa1a cells (our
unpublished data).
Next, indirect immunofluorescence microscopy was used to identify any
differences that might exist in the distribution of UGT between Hepa1a
and HEK293 cells, because a diminished concentration of the
glycoprotein folding sensor in the ER could conceivably hinder the
efficiency by which PI Z reenters the calnexin cycle. In Hepa1a, UGT
exhibited a reticular distribution (Figure
6A), similar to that of calnexin (Figure
7B), and distinct from Golgi mannosidase
II (Figure 6C). In contrast, only minimal reticular staining of UGT was
detected in HEK293, and the bulk was distributed in a perinuclear
manner (Figure 6D), similar to that of Golgi mannosidase II (Figure
6F). Consistent with the conclusion that the bulk of UGT was
sequestered downstream of the ER, UGT staining was redistributed into a
distinct reticular pattern in response to the treatment of cells with
brefeldin A (Figure 6E), which induces the redistribution of proximal
Golgi contents into the early secretory pathway (Lippincott-Schwartz
et al., 1989
). That the altered distribution of UGT in
HEK293 was not representative of the general ER chaperone content was
confirmed by the reticular staining of calreticulin, calnexin, and
grp78/BiP in both cell lines (Figure 7). Importantly, in parallel
studies, the pattern of chaperone staining was unaffected in both host
cell lines following stable transfection with PI Z (our unpublished
data), indicating that the selective distribution of UGT in
HEK293 reflects a cell-specific organizational distinction, rather than
a differential response to PI Z synthesis.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Posttranslational Quality Control as a Modifier of Protein Fate
In the ER, a compartment through which all secretory and cell
surface proteins must pass, folding and quality control systems work in
parallel as a posttranslational checkpoint in eukaryote genome
expression (reviewed by Cabral et al., 2001
). Therefore, a
central goal of the present study was to determine whether the mechanism by which a newly synthesized glycoprotein is handled after
biosynthesis is sufficient to modify its defective secretion, and
thereby potentially contribute to the phenotypic variation of disease,
or even disease penetrance. Variant PI Z was chosen as a reporter
protein because the spontaneous loop-sheet polymerization (Lomas
et al., 1992
) of a late folding intermediate (Yu et
al., 1995
) leads to its defective secretion from liver hepatocytes and is directly responsible for chronic obstructive pulmonary disease
as a loss-of-function phenotype (reviewed by Culliton, 1989
; Kopito and
Ron, 2000
).
In stably transfected HEK293, the degradation of secretion-impaired PI
Z was mediated by the ubiquitin-proteasome system, rather than by a
coexisting nonproteasomal system used in the hepatoma cell line Hepa1a
(Cabral et al.,2000
). Furthermore, as much as 40% of the
newly synthesized molecules were eventually secreted into the medium
under control conditions, which is a significant increase over the
10-15% secreted from Hepa1a (Le et al., 1990
, 1992
; Cabral
et al., 2000
). Because loop-sheet polymerization blocks
formation of the secretion-competent
1-antitrypsin monomer (Yu
et al., 1995
), a 50% enhancement in secretion from HEK293 under conditions that stopped degradation by the proteasome suggests that polymerization plays no significant role in mediating ER retention
in the foreign folding and quality control environment. Consistent with
this idea, calnexin and grp78/BiP sequentially bound
secretion-incompetent PI Z, although neither of these molecules is
expected to persistently interact with the polymer. However, we cannot
disregard the possibility that the small fraction of molecules never
secreted from HEK293, under any circumstances, might consist of the
polymerized material. Finally, it is noteworthy that the extent to
which PI Z is secreted from HEK293 is hypothetically sufficient to
prevent the elastolytic destruction of lung connective tissue, if
faithfully duplicated in vivo. As such, the present study provides a
proof-of-principle to support the notion that the manner in which a
newly synthesized gene product is processed is potentially sufficient
to modify the severity of a loss-of-function phenotype, implicating a
possible role for protein biosynthetic quality control as a modifier of disease.
Recognition of a Two-Component GERAD Signal
In the present study, variant PI Z bound grp78/BiP before its
degradation in HEK293, and required oligosaccharide modification, possibly by ER mannosidase I. Because the glycan modification is not
sufficient to target native glycoproteins for degradation, we (Cabral
et al.,2001
) recently proposed that nonnative protein structure likely participates as an additional aglycone
(noncarbohydrate) GERAD signal component. If one accepts the
two-component signal hypothesis, and assumes that GERAD functions in a
manner similar to other multistep biological processes, then the
initiation of a downstream step requires the completion of a preceding
event. As such, the enhanced physical interaction with grp78/BiP under conditions that inhibit formation of the glycan-based signal component might indicate that the molecular chaperone functions, at least in
HEK293, as an aglycone (noncarbohydrate) signal recognition factor.
Because interaction with grp78/BiP and subsequent modification by ER
mannosidase I are completed well before the onset of proteasomal
degradation (Figure 1B), it is likely that recognition of the modified
oligosaccharide, functions as the rate-limiting step for substrate
recruitment into GERAD. Consistent with this idea, Nagata and coworkers
recently demonstrated that the elevated expression of an inactive
mammalian homolog of ER mannosidase I, designated EDEM, was sufficient
to accelerate the proteasomal degradation of terminally misfolded
1-antitrypsin variant null(Hong Kong) in HEK293 (Hosokawa et
al., 2001
). The idea is that EDEM likely functions as a
glycan-based GERAD signal recognition factor by recognizing the Man8B
product generated by ER mannosidase I, a role recently implicated for
its yeast homologs Htm1p (Jakob et al., 2001
) and
Mnl1p (Nakatsukasa et al., 2001
). In this manner, asparagine-linked oligosaccharide modification would play a pivotal role in the partitioning of grp78/BiP-bound PI Z between folding and
degradation pathways.
In the present study, PI Z secretion was enhanced 50% after mannosidase inhibition (Figure 5B). Therefore, one can assume that a significant fraction of the molecules is maintained in a folding-competent state when bound to grp78/BiP, and can eventually attain secretion-competence, if not degraded. In the event that grp78/BiP does function as an aglycone signal recognition factor, as we suspect, its partnering in the recognition of a two-component GERAD signal provides an attractive explanation as to how a molecular chaperone can participate in both protein folding and degradation pathways, thereby addressing a central unanswered question in protein folding and quality control research. Although a direct correlation was detected between grp78/BiP binding, glycan modification, and degradation, we cannot entirely rule out the possibility that an alternate factor, or even EDEM itself, might be capable of functioning as the aglycone GERAD signal recognition factor. Finally, it should be noted that the cellular machinery that facilitates the recognition and recruitment of aberrant nonglycosylated proteins into ERAD, a close relative of GERAD, has not yet been identified, nor was this a goal of the present study.
Evidence for Distinct GERAD Programs
Our (Liu et al., 1999
; Cabral et al., 2000
)
original finding that the proteasome-mediated degradation of aberrant
AAT in the hepatoma cell line Hepa1a requires physical interaction with
calnexin was met with some speculation because the interaction is known to suppress substrate degradation in many cell lines (reviewed by
Ellgaard et al., 1999
; Frigerio and Lord, 2000
). Initially, we thought that the proteasomal degradation of PI Z in HEK293 might
simply reflect its inability to divert PI Z polymers into a
nonproteasomal degradation pathway, which is used in Hepa1a (Cabral
et al., 2000
). However, this is probably not the case because PI Z polymers are of low abundance in HEK293, if they exist at all.
Considering the distinct roles and intracellular locations of calnexin
and UGT, respectively, it is unlikely that alternate branches of the
same degradation system operate in the two cell lines. Rather, we
propose that the data are more compatible with a model in which
distinct GERAD programs are administered. Whether this difference
reflects a component of cell differentiation, or merely a difference in
cell adaptation mechanisms is not yet known. However, possibly favoring
the former idea, a post-ER distribution for UGT has been detected in
additional extrahepatic cells lines (Cannon and Helenius, 1999
; Zuber
et al., 2001
), including that in which variant PI Z is
degraded by the proteasome (Novoradovskaya et al., 1998
).
Although one might question the value of sequestering a glycoprotein
folding sensor downstream of the ER, it was recently suggested that
some newly synthesized glycoproteins might actually utilize this
situation as they fold when cycling between early compartments in the
secretory pathway (Cannon and Helenius, 1999
). As such, the
exploitation of specific steps in the GERAD program, and not the entire
program itself, might explain why some proteins exhibit different fates
in distinct cell lines, whereas others do not (Sitia et al.,
1990
; Qu et al., 1996
; Novoradovskaya et al.,
1998
; Cabral et al., 2000
).
Divergence at Level of GERAD Signal Recognition
One interpretation of our present findings is that the putative
cell-specific GERAD programs converge at the earliest steps, including
signal formation, but diverge in the manner by which the signals are
recognized. In Hepa1a, the proteasomal degradation of aberrant AAT
requires physical engagement with calnexin (Liu et al.,
1999
; Cabral et al., 2000
), suggesting that the ER lectin might replace EDEM as the glycan-based signal recognition factor. In
this scenario, it would follow that UGT replaces grp78/BiP as the
partnering aglycone signal recognition factor, which results in the
formation of a ligand for calnexin that, when modified by ER
mannosidase I, is a poor substrate for glucosidase II (Liu et
al., 1999
), thereby leading to molecular capture by the ER lectin.
Of course, we cannot entirely ignore the possibility that an
alternative, or additional, protein such as the oxidoreductase ERp57,
which is bound to calnexin and facilitates intramolecular disulfide
bond formation (Oliver et al., 1997
), might function, or
play a role, because the aglyone-based signal recognition step. However, this seems unlikely because only a single cysteine residue exists in human AAT (Long et al., 1984
).
Final Remarks
By studying early protein folding events, Helenius' group
recently discovered that the site of asparagine-linked glycosylation on
the nascent polypeptide contributes to the rules that govern cotranslational chaperone selection in the ER (Molinari and Helenius, 2000
). In the present study, our analysis of glycoprotein disposal led
to the discovery of a posttranslational mechanism capable of causing
the transfer of a GERAD substrate into distinct folding pathways.
Although not directly studied, it is entirely possible that the initial
role for the transfer event is to provide the newly synthesized protein
with an additional folding landscape to facilitate conformational
maturation as a last resort, just before the onset of degradation.
Whether latent engagement with grp78/BiP is responsible for hindering
PI Z loop-sheet polymerization in HEK293, is not yet understood, and
will require additional analysis.
Because the mechanism by which a mutant gene product is processed, rather than the mutation itself, can potentially play a profound role in the severity of a loss-of-function disorder, it is now evident that GERAD has the potential to function as an epigenetic modifier of disease, especially in the event of its inappropriate development or dysregulation. Whether the utilization of distinct GERAD programs reflects a previously unappreciated component of cell differentiation, is not yet known, but will be the focus of future studies.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported in part by National Institutes of Health grants HL-62553 (to R.N.S.), GM-47533 (to K.W.M.), and RR-05351 (to K.W.M.); the Alpha-1 Foundation Fernandez Liver Research Initiative (to R.N.S.); and an Alpha-1 Foundation Young Investigator training grant (to C.M.C.).
| |
FOOTNOTES |
|---|
§ Corresponding author. E-mail address: rsifers{at}bcm.tmc.edu.
Article published online ahead of print. Mol. Biol. Cell 10.1091/mbc.E02-02-0068. Article and publication date are at www.molbiolcell.org/cgi/doi/10.1091/mbc.E02-02-0068.
| |
REFERENCES |
|---|
|
|
|---|
1-antitrypsin causes liver damage in transenic mice.
J. Clin. Invest.
82, 26-36.
1-Antitrypsin deficiency - a model for conformational diseases.
N. Engl. J. Med.
346, 45-53
-mannosidases: phylogeny and adaptive diversification.
Mol. Biol. Evol.
17, 292-300
1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP.
J. Biol. Chem.
265, 20463-20468
1,2-mannosidases involved in glycoprotein synthesis and endoplasmic reticulum quality control.
Biochimie
83, 757-762[Medline].
-mannosidase-like protein accelerates ER-associated degradation.
EMBO Rep.
2, 415-422[CrossRef][Medline].
1-antitrypsin variant are degraded within the endoplasmic reticulum by a mechanism sensitive to inhibitors of protein synthesis.
J. Biol. Chem.
267, 1072-1080
1-antitrypsin variant. Biochemical mapping of the degradative event among compartments of the secretory pathway.
J. Biol. Chem.
265, 14001-14007
1-antitrypsin.
J. Biol. Chem.
269, 7514-7519
1-antitrypsin involves release from calnexin and post-translational trimming of asparagine-linked oligosaccharides.
J. Biol. Chem.
272, 7946-7951
1-antitrypsin accumulation in the liver.
Nature
357, 605-607[CrossRef][Medline].
1-antitrypsin and the gene for the S variant.
Biochemistry
23, 4828-4837[CrossRef][Medline].
-mannosidase II. Characterization and comparison with the intact enzyme.
J. Biol. Chem.
266, 16876-16885
-mannosidase-like protein in yeast Saccharomyces cerevisiae, is required for endoplasmic reticulum-associated degradation of glycoproteins.
J. Biol. Chem.
276, 8635-8638
1-antitrypsin associated with a profound deficiency.
J. Clin. Invest.
101, 2693-2701[Medline].
1-antitrypsin gene and emphysema.
Am J Physiol.
257, L147-L162
1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity.
J. Biol. Chem.
271, 22791-22795
1-antitrypsin that is retained within the rough endoplasmic reticulum.
J. Biol. Chem.
263, 7330-7335
1-antirypsin deficiency.
Sem. Liv. Dis.
12, 301-310.